Across Borders and Histologies: Rethinking Endpoints for Vascular Sarcoma Trials.

Eribulin was evaluated in angiosarcoma and epithelioid hemangioendothelioma (EHE) through two prospective international trials. Although encouraging activity was observed in EHE, its role in angiosarcoma may depend on further refinement through subgroup selection. These findings underscore the importance of histology-specific interpretation, innovative endpoints, and coordinated strategies for ultrarare sarcoma drug development. See related article by Cote et al., p. 2206.